巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Mersana Therapeutics

    MRSN
    6.160
    0.010
    0.08%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Mersana Therapeutics - 延遲價格・最後更新於 26/09 12:00
    最高位
    6.460
    最低位
    6.150
    開市價
    --
    前收市價
    6.155
    成交量(千)
    67.42
    成交額(百萬)
    3.57
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    598.56
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    10.060 - 2.680
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Mersana Therapeutics
    證券代碼
    MRSN.US
    所屬板塊
    Biotechnology
    公司業務
    Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
    發行量
    96991298
    公司總部
    840 Memorial Drive
    公司網址
    https://www.mersana.com
    公司電郵
    scarmody@mersana.com
    公司電話
    +1 617 498-0020
    暫無內容

    關於

    Mersana Therapeutics(MRSN.US)所屬的行業板塊為Biotechnology。
    Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
    詳細公司背景可參考: https://www.mersana.com